Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 33 Dermatologic 24 Other hematologic neoplasm 23 Lymphoid 14 Myeloid 13 Plasma cell 12 Gastrointestinal 12 Thoracic 5 Sarcoma 3 Gynecologic 3 CNS 3 Other solid neoplasm 2 Other neoplasm 2 Head & Neck 2 Breast 2 NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 32 Octreotide 15 Cisplatin 14 pasireotide 13 Sunitinib 13 Temozolomide 11 pembrolizumab 10 Etoposide 10 Doxorubicin 10 lanreotide 9 Magnetic Resonance Spectroscopy 9 Bevacizumab 9 lutetium Lu 177 dotatate 8 gallium Ga 68 dotatate 8 Sorafenib 8 Paclitaxel 8 3-Iodobenzylguanidine 8 lenvatinib 7 pazopanib 6 Radiotherapy 6 Positron Emission Tomography Computed Tomography 6 Nivolumab 6 surufatinib 5 cabozantinib 5 avelumab 5 Thyrotropin Alfa 5 Surgical Procedures, Operative 5 Radiosurgery 5 Mitotane 5 Irinotecan 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Interferon-alpha × Endocrine × Clear all

NCT02838342 2021-08-02

EPICentro

Centre Hospitalier Universitaire de Besancon

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡